Retrospective studies suggest that there is high mortality in children with sickle cell anemia (SCA) and severe malaria. We assessed mortality in Ugandan children with severe malarial anemia (SMA, n = 232) or cerebral malaria (CM, n = 267) by sickle cell hemoglobin genotype. Admission and 2-year follow-up mortality did not differ among children with SMA who had homozygous form of sickle cell hemoglobin (HbSS) versus normal form of adult hemoglobin (admission, 0/22, 0%, vs.
INTRODUCTION
Sickle cell hemoglobin (HbS) is the most common pathological hemoglobin variant worldwide. 1 Heterozygotes (heterozygous form of HbS, HbAS) are usually asymptomatic and protected against malaria, 2, 3 whereas homozygotes (homozygous form of sickle cell hemoglobin, HbSS; sickle cell anemia, SCA) are prone to end organ damage [4] [5] [6] and, in many parts of sub-Saharan Africa, early death. 4 Children with HbSS may not have an increased risk of developing malaria, but two studies with small numbers of children with SCA and severe malaria (n = 5 and 21, respectively) suggest that they have a high mortality rate with severe malaria. 7, 8 To further address the question of mortality with severe malaria in children with SCA, we compared risk of inpatient and follow-up mortality according to HbS genotype in a prospectively enrolled cohort of children with severe malaria (cerebral malaria [CM] or severe malarial anemia [SMA] ) and healthy community controls (CCs).
Abbreviations: CC, community control; CM, cerebral malaria; HbS, sickle cell hemoglobin; HbSS, homozygous form of HbS; HbAS, heterozygous form of HbS; HbAA, normal form of adult hemoglobin; SCA, sickle cell anemia; SMA, severe malarial anemia
METHODS AND RESULTS

Study participants
The study was carried out at Mulago National Referral Hospital in Kampala, Uganda. All participants were enrolled in a study assessing neurodevelopmental impairment in severe malaria, conducted from November 2008 to December 2013. Details of the methods of the primary study including inclusion criteria and study enrollment are described elsewhere. 9 Briefly, children 18 months to 12 years of age were enrolled. CM was defined as a child with unarousable coma and Plasmodium falciparum parasitemia on blood smear. SMA was defined as a child with a hemoglobin level ≤5 g/dl and P. falciparum parasitemia on blood smear. Community children were healthy children from the neighborhoods of children with severe malaria children. Children with known chronic disease, including known SCA, were excluded.
Clinical management
Children with CM or SMA were managed according to Ugandan Ministry of Health treatment guidelines for malaria, which at the time of study included intravenous quinine treatment followed by oral quinine. All children with SMA received a blood transfusion (20 ml/kg of whole blood or 10 ml/kg of packed red blood cells), usually within 2 hr of admission.
Follow-up
Study participants were followed up for 2 years after discharge from hospital to assess for illness, including malaria, readmissions, and deaths.
HbS testing
Genomic DNA was isolated from whole blood samples for SMA and CM patients or filter papers for CCs using the DNeasy Blood and tissue kit (Qiagen, Valencia, CA). The beta hemoglobin region of interest was amplified using specific primers. Children with HbSS were referred to the Mulago Hospital Sickle Cell Clinic, and HbSS was confirmed by hemoglobin electrophoresis.
Statistical analysis
Analysis was done in STATA 12 (Stata Corporation). Proportions were compared with 2 analysis and mean or median values with Student's ttest or the Wilcoxon rank-sum test, respectively. Incidence rates were compared between groups by negative binomial regression.
Ethical review
Written informed consent was obtained from parents or guardians of study participants. Institutional Review Boards for human studies at
Makerere University and the University of Minnesota granted ethical approval for the study.
Admission findings
Two hundred sixty-seven children with CM, 232 children with SMA, and 216 CC were enrolled and had samples available for HbS genotyp- Among children with SMA, children with HbSS were older and had a higher white blood count than children with HbAA, however P. falciparum parasite density was similar in the two groups (Table 1) . Among children with SMA, mortality did not differ between children with HbSS (0%) and children with HbAA (0.5%, Table 1 ). The one child with CM and HbSS survived. 
Follow-up findings
DISCUSSIONS
We found, in contrast to previous studies, 7, 8 that children with SCA did not have increased inpatient mortality with severe malaria compared to children with HbAA. Even postdischarge mortality in children with HbSS and severe malaria did not differ significantly from that of children with HbAA (4.5% vs. 3.6%, P = 0.77), though incidence of all-cause readmissions was higher with HbSS. The findings bring in to question whether children with HbSS have an increased risk of mortality with severe malaria compared to children with HbAA. The findings must be interpreted with caution as the study did not include children with known SCA at the time of admission, and all children were >18 months of age, both factors that could select for a healthier population of children with SCA, as children with SCA in this setting are reported to have significant morbidity and mortality in the first 2 years of life. 10, 11 Previous studies have shown that if blood transfusion service is readily available, as was the case in this study, mortality in SMA is generally low. 12, 13 In the present study, this was the case regardless of the presence of concurrent SCA. Prior studies of severe malaria in children with SCA have shown a range of mortality: from 4 of 86 (4.6%) 14 to 2 of 21 (9.5%) 8 of children with SCA admitted with parasitemia to 4 of 5 children (80%) admitted with WHO criteria for severe malaria. 7 In the only other study assessing mortality in children with SMA and SCA, SMA was the primary complication of malaria, and none of the 38 children with SMA and SCA died (0% mortality), 14 a finding identical to the present study. Sample sizes of children with both severe malaria and SCA have been small in all studies, emphasizing the need for large prospective studies of malaria morbidity and mortality in SCA. However, studies such as the present study, in which children with severe malaria are assessed for SCA, are another way of getting at the question, as these studies may "enrich" for children with severe malaria, which appears to be a relatively uncommon complication of SCA.
In conclusion, our study findings suggest that in children >18 months of age with SCA, inpatient mortality from SMA, the most common form of severe malaria, is low and similar to that of children with HbAA if timely blood transfusion is provided, and that postdischarge mortality in children with SMA is also similar in children with HbSS versus HbAA. However, the exclusion of children with known SCA is an important study limitation, as is the limited study sample size. Therefore, the present study is a call for large prospective studies of malaria morbidity and mortality in children with SCA to definitively address the extent to which severe malaria causes mortality in SCA.
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